Human monoclonal antibodies: recent achievements.
The latest developments include an anti-HIV antibody that has 1,000 times the affinity of natural antibody and that neutralizes primary clinical isolates, and an anti-RSV antibody that reduces viral titers in mice by 12,000-fold within 24 hours.